Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences

LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief Executive Officer, will present at the 46th Annual TD Cowen Healthcare Conference and the 36th Annual Oppenheimer Healthcare Life Sciences Conference.

The Company will provide an update on its dermatology pipeline, including the status of the ongoing Phase 2 clinical trial evaluating GX-03, the company’s lead investigational therapy for moderate-to-severe atopic dermatitis (eczema). Management will also participate in one-on-one meetings with institutional investors.

Conference Participation:

• 36th Annual Oppenheimer Healthcare Life Sciences Conference (Virtual) Wednesday, February 25, 2026 8:00 a.m. – 8:30 a.m. Eastern Time
• 46th Annual TD Cowen Healthcare Conference in Boston, MA Monday, March 2, 2026 1:10 p.m. – 1:40 p.m. Eastern Time Boston Marriott Copley Place, Boston, MA

A live webcast of the presentations may be accessed on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/presentations. A replay of the webcasts will be available on the Turn Therapeutics website for approximately 30 days following the presentation.

About Turn Therapeutics

Turn Therapeutics is a biotechnology company focused on developing innovative, precision therapies that target the underlying causes of inflammatory diseases with high unmet needs. Their lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor currently in late-stage development for the treatment of moderate-to-severe atopic dermatitis (eczema). This therapy is designed to modulate key inflammatory pathways involved in eczema and other inflammatory dermatological conditions.

Contacts

Investor Relations/Media Contact

Sasha Damouni Damouni Group, LLC [email protected]